Cassava Sciences Inc., a clinical-stage biotechnology company, has announced the appointment of Dr. Angélique Bordey as Senior Vice President, Neuroscience, to enhance its preclinical program in TSC-related epilepsy. Dr. Bordey, who will continue her academic role at Yale School of Medicine, will lead the scientific evaluation of simufilam, a potential novel treatment for this challenging epilepsy syndrome. Her expertise is expected to advance Cassava's research and development efforts, following a recent patent and license agreement with Yale University. This initiative marks a significant step in exploring new treatment options for TSC-related epilepsy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.